Pharma channel feed – Endpoints News

Pharma channel feed

EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status

8 years ago

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

8 years ago

Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression

8 years ago

Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues

8 years ago

Dicerna shares rocket up on a $15M-plus-stock deal to settle Alnylam claims — will deals follow?

8 years ago

Arcturus takes another legal stab at former CEO as public battle turns serious for the company

8 years ago

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

8 years ago

CHMP scolds AB Science (again) for masitinib shortcomings, triggering a new rout on stock price

8 years ago

UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal

8 years ago

Biogen pays $1B cash to enlist Ionis on a new drug discovery campaign — but can it deliver fast enough for analysts?

8 years ago

GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now

8 years ago

FDA’s insider review raises serious safety issues as Eli Lilly’s quick comeback shot for baricitinib heads for expert showdown

8 years ago

Badrul Chowdhury jumps ship at the FDA and moves to AstraZeneca, joining an exodus of agency officials

8 years ago

AstraZeneca wins expanded OK to use Tagrisso in frontline lung cancer niche, spurring hope of hitting $3B sales goal

8 years ago

Sangamo probes for fresh breaches of its digital security system after top exec’s email was hacked -- exposing secrets

8 years ago

FDA chief Scott Gottlieb promises to streamline drug development pathway for biopharma

8 years ago

In FDA double header, regulators also offer a green light to Rigel's fostamatinib

8 years ago

Ultragenyx wins a blockbuster OK for its leading rare disease drug burosumab -- priced at $200,000

8 years ago

GW Pharma's cannabis-based drug appears poised for a groundbreaking FDA approval as internal review offers a clear thumbs up

8 years ago

Unencumbered by safety concerns, Roche's Hemlibra gets breakthrough status for new patient group

8 years ago

Bristol-Myers invites J&J into an alliance of giants on cardio drug development/commercialization program

8 years ago

Servier buys Shire's oncology unit for $2.4B in the run-up to Takeda's final buyout offer — if it makes one

8 years ago

In a stunning about face, the FDA is now welcoming the new drug application from Alkermes it rejected 2 weeks ago

8 years ago

Next-generation sequencing: FDA offers guidance to streamline path to market

8 years ago

First page Previous page 302 303 304305306 307 308 Next page Last page